CoChat

Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1c Targets. A Guidance Statement from the American College of Physicians

Qaseem, Amir, Vijan, Sandeep, Snow, Vincenza, Cross, J. Thomas, Weiss, Kevin B., Owens, Douglas K., for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* · 2007 · Annals of Internal Medicine
Cited by 157

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

This guidance statement is derived from other organizations' guidelines and is based on an evaluation of the strengths and weaknesses of the available guidelines. We used the Appraisal of Guidelines, Research and Evaluation in Europe (AGREE) appraisal instrument to evaluate the guidelines from various organizations. On the basis of the review of the available guidelines, we recommend: Statement 1: To prevent microvascular complications of diabetes, the goal for glycemic control should be as low as is feasible without undue risk for adverse events or an unacceptable burden on patients. Treatment goals should be based on a discussion of the benefits and harms of specific levels of glycemic control with the patient. A hemoglobin A1c level less than 7% based on individualized assessment is a reasonable goal for many but not all patients. Statement 2: The goal for hemoglobin A1c level should be based on individualized assessment of risk for complications from diabetes, comorbidity, life expectancy, and patient preferences. Statement 3: We recommend further research to assess the optimal level of glycemic control, particularly in the presence of comorbid conditions. *This paper, written by Amir Qaseem, MD, PhD, MHA; Sandeep Vijan, MD, MS; Vincenza Snow, MD; J. Thomas Cross, MD, MPH; Kevin B. Weiss, MD, MPH; and Douglas K. Owens, MD, MS, was developed for the American College of Physicians' Clinical Efficacy Assessment Subcommittee: Douglas K. Owens, MD, MS (Chair); Donald E. Casey Jr., MD, MPH, MBA; J. Thomas Cross Jr., MD, MPH; Paul Dallas, MD; Nancy C. Dolan, MD; Mary Ann Forciea, MD; Lakshmi Halasyamani, MD; Robert H. Hopkins Jr., MD; and Paul Shekelle, MD, PhD. Approved by the ACP Board of Regents on 28 October 2006.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-147-6-200709180-00012

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 5

  1. 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  2. 10.1056/NEJM199309303291401 · DOI · Paper page
  3. 10.4158/EP.8.S1.40 · DOI · Paper page
  4. American Diabetes Association, 2006, Diabetes Care, 29, S4, 10.2337/diacare.29.s1.06.s4 · DOI · Paper page
  5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2003, Can J Diabetes, 27, S1

Cited by

See all 157

Metadata

Authors
Qaseem, A., Vijan, S., Snow, V., Cross, J. T., Weiss, K. B., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians*
Venue
Annals of Internal Medicine
Published
2007-09-18
Volume
147
Issue
6
Pages
417-422
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2002078774
Cited by
157
References
3
FWCI
13.09
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1c Targets. A Guidance Statement from the American College of Physicians. https://app.cochat.ai/papers/10.7326/0003-4819-147-6-200709180-00012
The paper
Qaseem, A., Vijan, S., Snow, V., Cross, J. T., Weiss, K. B., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians*. (2007). Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1c Targets. A Guidance Statement from the American College of Physicians. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-6-200709180-00012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.